Skip to main content Skip to search Skip to main navigation

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA and PIC/S have published a concept paper announcing a targeted revision of Annex 6 Manufacture of Medicinal Gases of the EU GMP Guide. The last update dates from 2010. The revision aims to reflect current manufacturing practice, technological progress and lessons learned from the COVID-19 pandemic.

Key elements under discussion

The revision will be focused and limited in scope, addressing in particular:

  • Premises requirements
    Reassessment of the applicability of general GMP requirements to closed, pressurised gas manufacturing systems.
  • Technological developments
    Consideration of modern safety features such as gas-specific couplings, elimination of containers without residual pressure valves and adapted valve/residual gas checks to reduce contamination risks.
  • Cylinders with integrated pressure regulator flowmeters
    Clarification of inspection requirements before and after refilling and definition of control frequencies; inclusion of cryogenic containers.
  • Medicinal liquid oxygen supply to hospitals
    Strengthening and clarification of documentation and quality assurance requirements for the filling of the hospital’s tank evaporation units.
  • Batch certification (in addition to Annex 16)
    Assessment of potential specific provisions for medicinal gases, including QP availability and possible remote certification aspects.
  • Qualification of facilities and containers
    Clarification regarding qualification of production plants, mobile/stationary tanks and reusable containers.

Timeline

  • Public consultation until 11 April 2026
  • Draft guideline: November 2026
  • Finalisation: 2027


Quelle:

EMA: Concept paper on revision of the guidelines on Good Manufacturing Practice for medicinal products - Annex 6 Manufacture of Medicinal Gases

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

What are the Core Tasks of Human Resource Management?

What are the Core Tasks of Human Resource Management?

Here's the answer:
Read more
European GMP Regulations: Ongoing Changes and What Lies Ahead

European GMP Regulations: Ongoing Changes and What Lies Ahead

At the 2026 ISPE European Annual Conference in Copenhagen, Brendan Cuddy (EMA) provided a concise update on current European GMP regulatory developments and the work of the GMP/GDP Inspectors Working Group (GMDP IWG).
Read more
EMA: Scientific Guideline on Development and Manufacture of Synthetic Peptides

EMA: Scientific Guideline on Development and Manufacture of Synthetic Peptides

The EMA has published the final version of the scientific guideline „Development and manufacture of synthetic peptides“.
Read more
EU: Strengthening Pharmaceutical Supply Chains and Global Health Resilience

EU: Strengthening Pharmaceutical Supply Chains and Global Health Resilience

The European Commission has published a new communication on reinforcing global health resilience, with a strong focus on resilient pharmaceutical supply chains, expanded manufacturing capacity, and security of supply for critical health products.
Read more
Annex 22: EMA Workshop on AI in GMP

Annex 22: EMA Workshop on AI in GMP

The European Medicines Agency (EMA) will hold a two-day multistakeholder workshop on 30 June and 1 July 2026 to gather expert input for the development of Annex 22 of the EU GMP Guide on the use of artificial intelligence (AI) in medicines manufacturing.
Read more
FDA: Pilot Program for One-Day Inspectional Assessments

FDA: Pilot Program for One-Day Inspectional Assessments

Since April 2026, the U.S. FDA has been piloting “One-Day Inspectional Assessments” as a complement to standard FDA inspections.
Read more
Previous
Next